Phase I, single dose, randomised, open-label, crossover trial investigating the tolerability and pharmacokinetics of once daily oral testosterone undecanoate [LPCN 1111] in postmenopausal women
Latest Information Update: 29 May 2014
At a glance
- Drugs Testosterone undecanoate (Primary)
- Indications Hypogonadism
- Focus Adverse reactions; Pharmacokinetics
- 29 May 2014 New trial record